OSE Immunotherapeutics – executive interview

In this interview, Sonya Montgomery, chief development officer at OSE Immunotherapeutics, covers the company’s lead immuno-inflammation candidate, lusvertikimab. She outlines the current unmet need in the therapeutic areas of ulcerative colitis and inflammatory bowel disease, as well as lusvertikimab’s clinical track record to date. She also discusses potential next steps for the programme, including OSE’s recently announced predictive biomarker, the potential of lusvertikimab to overcome the current therapeutic ceiling, and what a precision medicine approach might look like. She concludes by highlighting the key upcoming catalysts and milestones that investors should watch out for.

OSE Immunotherapeutics is a French clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immune-oncology and immuno-inflammation. Lusvertikimab successfully completed a Phase II trial in late 2024, meeting the primary endpoint with statistical significance and laying a robust foundation for further clinical development efforts. Under OSE’s renewed growth strategy, lusvertikimab remains one of the company’s top strategic priorities and management is committed to advancing its development responsibly.